EP300 and prostate carcinoma: Altogether, these findings suggest that p300/CBP retain partial catalytic function in the presence of reader bromodomain inhibitors and highlight the efficacy of CBPD-409-triggered rapid p300/CBP degradation in completely extinguishing their oncogenic histone acetylation program in prostate cancer cells.